Articles, commentary and company news.
Read NEUVIOR summaries and founder reflections, with direct links to the original publications.
Contributed analysis
In Express Pharma, Varun Sharma examines how India can strengthen pharmaceutical development by connecting formulation decisions, evidence, technology transfer, quality and investment.
Podcast appearance
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
Contributed analysis
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
Contributed opinion
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
All articles
Search articles, interviews, letters and company coverage by headline, publication or topic. Each entry includes its publication date, type and available reading links.
In Express Pharma, Varun Sharma examines how India can strengthen pharmaceutical development by connecting formulation decisions, evidence, technology transfer, quality and investment.
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
In ET Pharma, Varun Sharma argues that pharmaceutical quality depends on what an organisation can prove after inspection: whether failures recur, remediation holds and accountable people can trace each decision.
A Financial Times founder letter arguing that invention is only the beginning of the work required for adoption. The source is a published reader letter, not Financial Times staff coverage of NEUVIOR, and subscriber access may be required.
Pharmaceutical Technology coverage of Varun Sharma’s proposed five gate implementation ledger. The proposal is a founder viewpoint, not an adopted government, regulator or industry framework.
Secondary record
An AI labelled derivative recap of Varun Sharma’s Pharmaceutical Technology commentary, retained as a derivative record rather than an independent endorsement.
Secondary record
A derivative adaptation of the five gate implementation argument, linked to its originating Pharmaceutical Technology commentary.
Secondary record
A network republication concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
A founder commentary about why several medicines measures can each be legitimate while still requiring reconciliation, ownership and a shared operating view.
Manufacturing Chemist commentary on the operational work required after a positive NICE recommendation. Recommendation is one milestone; it is not marketing authorisation or evidence that NEUVIOR has delivered a service or outcome.
Digital Health’s editorial briefing included publicly reported SMART:SCOTLAND support for NEUVIOR.
A publisher record concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
Secondary record
An aggregated Glasgow ecosystem record concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
A Scottish business news brief recording publicly reported SMART:SCOTLAND support for NEUVIOR.
Scottish regional business coverage recording publicly reported SMART:SCOTLAND support for NEUVIOR.
Secondary record
A dated transaction database recap derived from TheBusinessDesk’s reporting. It is retained as derivative coverage rather than a separate independent endorsement.
Varun Sharma, Founder, CEO & CTO of NEUVIOR, reflects on how early lessons in his father's corner shop shaped his approach to building complex pharmaceutical and AI systems.
Trade coverage of bounded NEUVIOR pharmaceutical materials research.
Secondary record
A syndicated regional record concerning historical NEUVIOR research activity. The source wording should not be read as a current drug development or clinical programme.
Secondary record
A historical syndicated record concerning NEUVIOR research activity, retained as a public record entry rather than evidence of a current product, programme or operating division.
A dated Insider Media record covering bounded NEUVIOR pharmaceutical manufacturing waste research. Publication is not evidence of adoption, capability or outcomes.
A dated Yorkshire Post record covering bounded NEUVIOR pharmaceutical manufacturing waste research.
A dated York Press publisher record concerning NEUVIOR research activity. Despite the compressed source headline, it should not be read as evidence of a clinical or new drug trial, current manufacturing capability or outcomes.
A partner hosted record covering bounded NEUVIOR pharmaceutical materials research.
A local newsletter roundup linking to bounded NEUVIOR pharmaceutical materials research coverage.
Varun Sharma, Founder, CEO & CTO of NEUVIOR, argues that the hard part in pharmaceuticals and AI is rarely the idea. It is turning fragmented information, regulation and execution into a system that can deliver.
Where AI assistance ends, who owns the consequential decision and what genuine enterprise control requires.
How inspection, remediation evidence, human judgement and board accountability can support durable pharmaceutical quality.
What must happen between evidence, recommendation, a governed decision and reliable delivery.
How Varun Sharma’s operating experience, neurodivergence and family business origins shape NEUVIOR.
One originating implementation proposal and the international record that followed it.
Dated publisher records concerning historical research activity, while the work’s confidential scope and the boundary between activity and proof remain visible.
Publisher records concerning early feasibility support, without converting support into adoption, endorsement or technical validation.
After publication · A series by Varun Sharma
3 August 2026
If your mind sees the whole system at once, the next challenge is making that insight legible, owned and repeatable for everyone who must act on it.
Read the reflection3 August 2026
A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.
Read the reflection3 August 2026
Before you choose the number that supports a decision, make the population, price basis, time window and source visible.
Read the reflection3 August 2026
The smallest amount can reveal whether a business understands its margins, respects its records and keeps the promises hidden inside the numbers.
Read the reflection3 August 2026
A trade agreement can change the commercial and policy context. The value depends on whether each implementation gate has evidence, ownership and a route to learning.
Read the reflection3 August 2026
Feasibility becomes useful when the question, constraints, evidence threshold and stop or continue decision are explicit before the work begins.
Read the reflection3 August 2026
Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.
Read the reflection3 August 2026
Invention creates a possibility. Adoption requires authority, evidence, implementation, review and a reason for people to change what they do.
Read the reflectionReviewed source records include ET Pharma, BusinessCloud, Startups Magazine, Insider Media, the Yorkshire Post, York Press, Manufacturing Chemist, TheBusinessDesk.com, Daily Business, Digital Health, PharmaTimes, Pharmaceutical Technology and a Financial Times founder letter. Related and syndicated records remain clearly labelled.
On 4 August 2026, ET Pharma published Varun Sharma’s commentary, ‘India’s pharma quality reset will be won after the inspector leaves’. The NEUVIOR Newsroom links to the publisher record and identifies it as founder commentary. Publication does not indicate ET Pharma endorsement of NEUVIOR, PHARMORIS or VARUNÉ Labs.
No. The archive distinguishes independent reporting, reporting based on public announcements, founder commentary and syndicated copies. This prevents one underlying story from being presented as multiple endorsements.
Publisher headlines are retained as published, including occasional spellings such as Neuvoir or Neuvior. NEUVIOR is the correct company spelling.
Journalists can contact NEUVIOR through the Contact page or email [email protected] with their publication, deadline, topic and requested format.
After Publication is a linked series of later reflections by Varun Sharma. Each article starts from a publisher record, explains the operating question it raised and states what the publication does not prove about NEUVIOR or PHARMORIS.